Observes safety of lecanemab in people with early Alzheimer's disease
Observes brain imaging changes and treatment decisions in adults with early Alzheimer's taking lecanemab.
Plain-language title generated from the registry record
Registry title: A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
Key facts
- Where
- Hiroshima, Kyoto, and Tokyo, JapanSee the 3 sites
Where in Japan
- HiroshimaHiroshima, JapanTaking people
- KyotoKyoto, JapanTaking people
- TokyoTokyo, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eisai Co., Ltd.
- Trial code
- NCT06322667
- Record updated
- 23 January 2026
- Original description
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.Read full original descriptionShow less
A Multicenter, Postmarketing Observational Study to Evaluate Safety Regarding Amyloid-Related Imaging Abnormalities and Their Management in Patients With Early Alzheimer's Disease and Treated With Lecanemab
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.
Inclusion: All participants who are treated with lecanemab in routine clinical practice.
Exclusion: None.